1.
Eur J Nucl Med
; 26(4 Suppl): S50-3, 1999 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-10199933
RESUMO
Recently, it was recognized that an immune response develops along one of two major pathways. One leads to a destructive immune response (type 1), while the alternative leads to a nondestructive immune response (type 2). Our studies in animal models suggest that therapeutic vaccines induce a tumor-specific type 1 immune response while ineffective vaccines induce a type 2 response. These results have led us to examine the immune response in sentinel lymph nodes draining tumor vaccines of patients entered onto clinical trials for melanoma, breast and renal cell cancer.